Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of metronomic oral cyclophosphamide plus capecitabine combined with trastuzumab in advanced breast cancer
2009-017083-16Phase 2Completed
- Sponsor
- GOIM
- Start
- Apr 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, capecitabine and cyclophosphamide in breast cancer, sponsored by GOIM. Primary endpoint: Overall clinical benefit. Started Apr 2010; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-017083-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017083-16.